Home Tags EGFR

Tag: EGFR

NEOK002: A Next-Generation Bispecific ADC Targeting EGFR and MUC1 Enters Clinical...

NEOK002 (previously known as ABL209) is a novel, bispecific ADC designed to simultaneously target two key cancer antigens—Epidermal Growth Factor Receptor (EGFR), a key oncogenic driver in multiple tumor types, and Mucin-1 (MUC1), a tumor-associated antigen characterized by aberrant glycosylation and overexpression.

ASCO 2025: Rakuten Medical to Presents Updates of Phase 3 ASP-1929-381...

During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) which will take place May 30 – June 3, 2025, in Chicago, Illinois, Rakuten Medical* will be presenting a Trial in Progress poster with updates of the company's ongoing global Phase 3 clinical trial evaluating ASP-1929 photoimmunotherapy in combination with the anti-PD-1 pembrolizumab (Keytruda®; Merck & Co / MSD) as a first-line therapy for patients with recurrent head and neck squamous cell carcinoma (HNSCC).

China’s Regulator Approves IND for JS212, a Bispecific ADC

The National Medical Products Administration (NMPA) of China, a part of  the National Medical Products Administration (NMPA) of China has approved the Investigational New...

AbbVie Submits BLA to the US FDA for Telisotuzumab Vedotin in...

AbbVie has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V/ABBV-399; See Drugmap) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.

Sutro Biopharma Receives Milestone Payment for Bispecific Antibody-Drug Conjugate from Merck

South San Francisco-based clinical-stage biotechnology company Sutro Biopharma has received a milestone payment under its collaboration and license agreement with the healthcare division of...

Depatuxizumab Mafodotin Did Not Demonstrate Survival Benefit in INTELLANCE-1 Study

Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie, did not demonstrate a survival...

Amgen and CytomX Therapeutics Agree to Jointly Develop T-Cell Engaging Bispecific...

Amgen and CytomX Therapeutics have entered into a strategic collaboration to co-develop a Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR),...

Expanding Oncology Presence: AbbVie Acquires Stemcentrx

AbbVie, a global biopharmaceutical company has agreed to acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), also known as SC16LD6.5, which is currently...